Ontology highlight
ABSTRACT:
SUBMITTER: Uson Junior PLS
PROVIDER: S-EPMC10516216 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Uson Junior Pedro Luiz Serrano PLS Borad Mitesh J MJ
Cancer management and research 20230918
Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia and previously treated locally advanced or metastatic cholangiocarcinoma. In the Phase III trial ClarIDHy ivosidenib improved progression-free survival, 2.7 months versus 1.4 months (p < 0.0001) and overall survival (OS), median OS was 10.8 months for ivosidenib and 9.7 months for the placebo arm (p = 0.06) for patients with previously treated and IDH1 muta ...[more]